QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
NASDAQ:ISPC

iSpecimen (ISPC) Stock Forecast, Price & News

$1.45
-0.02 (-1.36%)
(As of 06/8/2023 ET)
Compare
Today's Range
$1.40
$1.48
50-Day Range
$1.22
$1.88
52-Week Range
$1.17
$3.26
Volume
11,846 shs
Average Volume
25,957 shs
Market Capitalization
$13.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.63

iSpecimen MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
425.9% Upside
$7.63 Price Target
Short Interest
Healthy
0.53% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$5,500 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.60 out of 5 stars

Medical Sector

88th out of 986 stocks

Commercial Physical Research Industry

3rd out of 15 stocks


ISPC stock logo

About iSpecimen (NASDAQ:ISPC) Stock

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

Receive ISPC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iSpecimen and its competitors with MarketBeat's FREE daily newsletter.

ISPC Stock News Headlines

Pentagon Consultant—Here's how Biden Wins Landslide Re-election
—but also hand Joe Biden a landslide re-election win. What would America look like if we slide further towards Socialism? Full story and 4 steps you can take,
iSpecimen Reports First Quarter 2023 Results
Contrasting iSpecimen (ISPC) and Its Rivals
Pentagon Consultant—Here's how Biden Wins Landslide Re-election
—but also hand Joe Biden a landslide re-election win. What would America look like if we slide further towards Socialism? Full story and 4 steps you can take,
iSpecimen (ISPC) and Its Rivals Head-To-Head Analysis
Contrasting iSpecimen (ISPC) & Its Peers
Reviewing iSpecimen (ISPC) and The Competition
Financial Analysis: iSpecimen (ISPC) versus Its Peers
iSpecimen (ISPC) vs. Its Competitors Head-To-Head Comparison
iSpecimen (ISPC) and Its Competitors Financial Survey
iSpecimen (ISPC) vs. Its Competitors Financial Contrast
Critical Review: iSpecimen (ISPC) and Its Peers
Head-To-Head Review: iSpecimen (ISPC) and Its Competitors
iSpecimen (ISPC) versus Its Rivals Head to Head Survey
Financial Survey: iSpecimen (ISPC) and Its Peers
Head-To-Head Survey: iSpecimen (ISPC) & The Competition
iSpecimen (ISPC) & Its Competitors Critical Comparison
Contrasting iSpecimen (ISPC) & The Competition
iSpecimen (ISPC) & Its Rivals Head to Head Contrast
Financial Review: iSpecimen (ISPC) vs. Its Peers
Analyzing iSpecimen (ISPC) and Its Peers
See More Headlines

ISPC Price History

ISPC Company Calendar

Last Earnings
3/14/2023
Today
6/08/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ISPC
Fax
N/A
Employees
75
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.63
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$4.25
Forecasted Upside/Downside
+429.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-10,250,000.00
Pretax Margin
-95.02%

Debt

Sales & Book Value

Annual Sales
$10.40 million
Book Value
$2.32 per share

Miscellaneous

Free Float
6,077,000
Market Cap
$13.02 million
Optionable
Not Optionable
Beta
1.93

Key Executives

  • Ms. Tracy Wilson Curley (Age 61)
    CEO, CFO, Treasurer & Director
    Comp: $313.38k
  • Dr. Christopher J. Ianelli M.D. (Age 55)
    Ph.D., Founder & Director
    Comp: $503.1k
  • Mr. Benjamin Bielak (Age 53)
    Chief Information Officer
    Comp: $307.94k
  • Ms. Dawn Michelle
    VP of Operations
  • Ms. Carly Lejnieks
    VP of Marketing
  • Ms. Annette Arnold
    VP of Sales & Bus. Devel.
  • Mr. David Wages M.D.
    Ph.D., Chief Medical Officer
  • Mr. Eric Langlois
    Chief Revenue Officer













ISPC Stock - Frequently Asked Questions

Should I buy or sell iSpecimen stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for iSpecimen in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ISPC shares.
View ISPC analyst ratings
or view top-rated stocks.

What is iSpecimen's stock price forecast for 2023?

1 analysts have issued 1 year price targets for iSpecimen's stock. Their ISPC share price forecasts range from $4.25 to $11.00. On average, they anticipate the company's stock price to reach $7.63 in the next twelve months. This suggests a possible upside of 429.0% from the stock's current price.
View analysts price targets for ISPC
or view top-rated stocks among Wall Street analysts.

How have ISPC shares performed in 2023?

iSpecimen's stock was trading at $1.3750 on January 1st, 2023. Since then, ISPC shares have increased by 4.8% and is now trading at $1.4415.
View the best growth stocks for 2023 here
.

Are investors shorting iSpecimen?

iSpecimen saw a drop in short interest in May. As of May 15th, there was short interest totaling 28,100 shares, a drop of 43.0% from the April 30th total of 49,300 shares. Based on an average trading volume of 30,900 shares, the short-interest ratio is presently 0.9 days. Currently, 0.5% of the shares of the stock are sold short.
View iSpecimen's Short Interest
.

When is iSpecimen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ISPC earnings forecast
.

How were iSpecimen's earnings last quarter?

iSpecimen Inc. (NASDAQ:ISPC) posted its earnings results on Tuesday, March, 14th. The company reported ($0.24) earnings per share (EPS) for the quarter. The firm earned $2.96 million during the quarter. iSpecimen had a negative trailing twelve-month return on equity of 47.82% and a negative net margin of 95.03%.

When did iSpecimen IPO?

(ISPC) raised $20 million in an initial public offering on Thursday, June 17th 2021. The company issued 2,200,000 shares at a price of $8.00-$10.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO.

What is iSpecimen's stock symbol?

iSpecimen trades on the NASDAQ under the ticker symbol "ISPC."

How do I buy shares of iSpecimen?

Shares of ISPC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iSpecimen's stock price today?

One share of ISPC stock can currently be purchased for approximately $1.44.

How much money does iSpecimen make?

iSpecimen (NASDAQ:ISPC) has a market capitalization of $13.02 million and generates $10.40 million in revenue each year. The company earns $-10,250,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis.

How can I contact iSpecimen?

The official website for the company is ispecimen.com. The company can be reached via phone at 781-301-6700 or via email at ispecimen@kcsa.com.

This page (NASDAQ:ISPC) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -